• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antipsychotic Use Associated With Increased Risk of Mortality

Antipsychotic Use Associated With Increased Risk of Mortality

March 11, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Gerhard T et al, PLoS One 2020;15(9):e0239206

TYPE OF STUDY: Population-based comparator cohort study

We know that atypical antipsychotics increase mortality in elderly patients with dementia—the FDA has long required a black box warning to that effect. But are these medications also dangerous when prescribed to younger people with depression?

To answer this question, researchers analyzed mortality rates of depressed adults (ages 25–64) enrolled in Medicaid between 2001–2010. Patients with major depression (but not other major Axis I disorders) who had failed to respond to > 3 months of antidepressant monotherapy were included. The researchers compared two cohorts: patients who had their antidepressant augmented with an antipsychotic (n = 22,410) vs those who had it augmented with a second antidepressant (n = 17,172). The outcome of interest was all-cause mortality rates over the next year for patients who remained on their medications.

In total, 105 deaths occurred during 7,601 person-years of follow-up in the antipsychotic augmentation cohort (138 per 100,000 person-years) versus 48 deaths during 5,727 person-years of follow-up in the antidepressant augmentation cohort (84 per 100,000 person-years). These numbers translate into an absolute risk of about 0.4% per year with antipsychotic augmentation, and a relative risk of 45% compared to antidepressant augmentation. To contextualize this figure, the relative risk in elderly patients with dementia is just slightly higher (around 54%), and this was concerning enough to the FDA to trigger a black box warning. Among the four antipsychotics with sufficient sample sizes, olanzapine and risperidone were associated with the highest risks of mortality, while quetiapine and aripiprazole the lowest—findings that are consistent with geriatric research.

The main weakness of the study was the lack of randomization, leaving open the possibility that prescribing bias could have contributed to the excess mortality in the antipsychotic augmentation group. For example, clinicians might have chosen atypicals for more severely depressed patients. Working in the opposite direction, however, clinicians might have preferred antidepressant augmentation for patients with medical comorbidities, which would artificially inflate mortality rates in this cohort instead. Furthermore, we should be cautious in generalizing results from Medicaid patients to the overall population.

TCPR’s Take
While this is only one study, and the increased mortality risk is small, the results should still give us pause before prescribing atypical antipsychotics in depression. It may be time to recalibrate their risk-benefit ratio.
General Psychiatry
KEYWORDS antidepressant-augmentation antipsychotics aripiprazole mortality
Michael Posternak, MD.

Trichotillomania: Diagnosis and Treatment

More from this author
www.thecarlatreport.com
Issue Date: March 11, 2021
SUBSCRIBE NOW
Table Of Contents
Stopping Psych Meds Part 2 TCPR, March 2021
TMS Treatment for Depression: An Update
How to Come Off a Psych Med Part 2: Antidepressants, Stimulants, and Benzos
A Closer Look at Alpha-2 Agonists for ADHD
Antipsychotic Use Associated With Increased Risk of Mortality
In Brief: Who Needs the Therapeutic Alliance?
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto11543850.jpg
    General Psychiatry

    Elvis, Adderall, and a Broken Heart - Part 1

    A new medical investigation changes our understanding of Elvis Presley’s untimely death and offer some pearls for modern psychiatric practice.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.